Examination of a non-invasive biomarker for the diagnosis of prodromal Alzheimer's disease and Alzheimer's disease Dementia.
作者信息
Dupree Emmalyn J, Darie Costel C
机构信息
Biochemistry & Proteomics Group, Department of Chemistry and Biomolecular Science, Clarkson University, 8 Clarkson Avenue, Potsdam, NY, USA, 13699-5810.
Biochemistry & Proteomics Group, Department of Chemistry and Biomolecular Science, Clarkson University, 8 Clarkson Avenue, Potsdam, NY, USA, 13699-5810; To whom inquiries should be addressed:.
出版信息
EBioMedicine. 2020 Jul;57:102882. doi: 10.1016/j.ebiom.2020.102882. Epub 2020 Jul 7.
Abstract
摘要
相似文献
1
Examination of a non-invasive biomarker for the diagnosis of prodromal Alzheimer's disease and Alzheimer's disease Dementia.用于诊断前驱性阿尔茨海默病和阿尔茨海默病痴呆的非侵入性生物标志物检测。
EBioMedicine. 2020 Jul;57:102882. doi: 10.1016/j.ebiom.2020.102882. Epub 2020 Jul 7.
2
Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.唐氏综合征成人阿尔茨海默病的血浆和脑脊液生物标志物：一项横断面研究。
Lancet Neurol. 2018 Oct;17(10):860-869. doi: 10.1016/S1474-4422(18)30285-0. Epub 2018 Aug 29.
3
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.轻度认知障碍阶段阿尔茨海默病的患病率及预后
Brain. 2015 May;138(Pt 5):1327-38. doi: 10.1093/brain/awv029. Epub 2015 Feb 17.
4
Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.血浆 tau 蛋白、神经丝轻链和淀粉样 β 水平与痴呆风险：一项基于人群的队列研究。
Brain. 2020 Apr 1;143(4):1220-1232. doi: 10.1093/brain/awaa054.
5
Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.脑脊液生物标志物（磷酸化tau181、总tau、Aβ42 和 Aβ40）在阿尔茨海默病和路易体痴呆前驱期的诊断价值。
J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731.
6
Plasma amyloid beta peptides: an Alzheimer's conundrum or a more accessible Alzheimer's biomarker?血浆β淀粉样肽：是阿尔茨海默病的难题还是更易获取的阿尔茨海默病生物标志物？
Expert Rev Neurother. 2017 Jan;17(1):3-5. doi: 10.1080/14737175.2016.1217156. Epub 2016 Jul 31.
7
The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.《阿尔茨海默病诊断中脑脊液生物标志物检测的临床应用：来自阿尔茨海默病生物标志物标准化倡议的共识文件》。
Alzheimers Dement. 2014 Nov;10(6):808-17. doi: 10.1016/j.jalz.2014.03.003. Epub 2014 Aug 20.
8
Multiplex immunoassay measurement of amyloid-β to amyloid-β ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease.血浆中淀粉样蛋白β与淀粉样蛋白β比值的多重免疫测定可区分阿尔茨海默病所致痴呆和非阿尔茨海默病所致痴呆。
Exp Brain Res. 2018 May;236(5):1241-1250. doi: 10.1007/s00221-018-5210-x. Epub 2018 Feb 26.
9
Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.阿尔茨海默病脑脊液生物标志物可预测路易体痴呆的认知衰退。
Mov Disord. 2016 Aug;31(8):1203-8. doi: 10.1002/mds.26668. Epub 2016 Jun 14.
10
A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.比利时阿尔茨海默病脑脊液生物标志物研究十年
J Alzheimers Dis. 2016 Aug 10;54(1):383-95. doi: 10.3233/JAD-151097.
引用本文的文献
1
Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease.标准化唾液乳铁蛋白测量以获得用于阿尔茨海默病的可靠诊断生物标志物。
Alzheimers Dement (Amst). 2021 May 2;13(1):e12173. doi: 10.1002/dad2.12173. eCollection 2021.
2
Body Fluid Biomarkers for Alzheimer's Disease-An Up-To-Date Overview.阿尔茨海默病的体液生物标志物——最新综述
Biomedicines. 2020 Oct 15;8(10):421. doi: 10.3390/biomedicines8100421.
本文引用的文献
1
Decreased salivary lactoferrin levels are specific to Alzheimer's disease.唾液乳铁蛋白水平降低是阿尔茨海默病特有的。
EBioMedicine. 2020 Jul;57:102834. doi: 10.1016/j.ebiom.2020.102834. Epub 2020 Jun 22.
2
Self- assembled lactoferrin-conjugated linoleic acid micelles as an orally active targeted nanoplatform for Alzheimer's disease.乳铁蛋白-共轭亚油酸自组装胶束作为一种用于阿尔茨海默病的口服靶向纳米平台。
Int J Biol Macromol. 2020 Nov 1;162:246-261. doi: 10.1016/j.ijbiomac.2020.06.058. Epub 2020 Jun 9.
3
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.氧化应激、葡萄糖代谢功能障碍与阿尔茨海默病。
Nat Rev Neurosci. 2019 Mar;20(3):148-160. doi: 10.1038/s41583-019-0132-6.
4
Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism.神经退行性疾病中的下丘脑改变及其与异常能量代谢的关系。
Front Mol Neurosci. 2018 Jan 19;11:2. doi: 10.3389/fnmol.2018.00002. eCollection 2018.
5
Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin.基于唾液乳铁蛋白的轻度认知障碍和阿尔茨海默病的早期诊断
Alzheimers Dement (Amst). 2017 May 26;8:131-138. doi: 10.1016/j.dadm.2017.04.002. eCollection 2017.
6
Relationship between salivary immunoglobulin a, lactoferrin and lysozyme flow rates and lifestyle factors in Japanese children: a cross-sectional study.日本儿童唾液免疫球蛋白A、乳铁蛋白和溶菌酶流速与生活方式因素的关系：一项横断面研究。
Acta Odontol Scand. 2016 Oct;74(7):576-583. doi: 10.1080/00016357.2016.1223340. Epub 2016 Aug 26.
7
APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease.载脂蛋白 E ε4：阿尔茨海默病最普遍但研究最少的风险因素。
Alzheimers Dement. 2014 Nov;10(6):861-8. doi: 10.1016/j.jalz.2014.06.015. Epub 2014 Sep 10.
8
Potential role of antimicrobial peptides in the early onset of Alzheimer's disease.抗菌肽在阿尔茨海默病早期发病中的潜在作用。
Alzheimers Dement. 2015 Jan;11(1):51-7. doi: 10.1016/j.jalz.2013.12.020. Epub 2014 Mar 15.
9
Characterization of the anti-HBV activity of HLP1-23, a human lactoferrin-derived peptide.鉴定人乳铁蛋白衍生肽 HLP1-23 的抗乙肝病毒活性。
J Med Virol. 2013 May;85(5):780-8. doi: 10.1002/jmv.23549.
10
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.阿尔茨海默病所致轻度认知障碍的诊断：美国国家老龄化研究所-阿尔茨海默病协会诊断指南工作组的建议。
Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.
Zotero 插件